---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-058157"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-08T23:50:29.063176+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology Q3 net loss $38.6M; cash $452.6M; ziftomenib trial enrollment on track for mid-2024

## Summary
- Net loss $38.6M vs $35.5M YoY; R&D $29.3M; cash $452.6M provides runway to mid-2026.
- Enrollment in KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete 85 patients by mid-2024.
- Preliminary data from 20 patients in KOMET-007 combination trial (ziftomenib + venetoclax/azacitidine or 7+3) expected early Q1 2024.
- First patient dosed in FIT-001 trial of next-gen FTI KO-2806; collaboration with Mirati for combo with adagrasib in KRAS G12C-mutated NSCLC.
- Brian Powl appointed Chief Commercial Officer in August 2023.

## SEC filing metadata
- accession: 0000950170-23-058157
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000095017023058157/0000950170-23-058157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000095017023058157/kura-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-058157
- JSON: https://secwatch.observer/filing/0000950170-23-058157.json
- Plain text: https://secwatch.observer/filing/0000950170-23-058157.txt

## Key facts
- Earnings Releases
  Kura Oncology, Inc. reported financial results for third quarter ended September 30, 2023.
  - Period: third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 2, 2023, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2023 and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000095017023058157/0000950170-23-058157-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.